Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease
J. Kálmán
Departments of Psychiatry and Neurology, Szent-Györgyi University Medical School, Szeged, Hungary
Search for more papers by this authorA. Juhász
Departments of Psychiatry and Neurology, Szent-Györgyi University Medical School, Szeged, Hungary
Search for more papers by this authorP. Dickens
Royal Scottish National Hospital, Old Denny Road, Larbert, Scotland
Search for more papers by this authorCorresponding Author
T. Járdánházy
Departments of Psychiatry and Neurology, Szent-Györgyi University Medical School, Szeged, Hungary
János Kálmán, Departments of Psychiatry and Neurology, Szent-Györgyi University Medical School, Semmelweis u.B. H-6725 Szeged, HungarySearch for more papers by this authorA. Rimanóczy
Departments of Psychiatry and Neurology, Szent-Györgyi University Medical School, Szeged, Hungary
Search for more papers by this authorI. Boncz
Departments of Psychiatry and Neurology, Szent-Györgyi University Medical School, Szeged, Hungary
Search for more papers by this authorW. L. I. Parry-Jones
Department of Child and Adolescent Psychiatry, University of Glasgow, Royal Hospital for Sick Children, Yorkhill, Glasgow, Scotland
Search for more papers by this authorZ. Janka
Departments of Psychiatry and Neurology, Szent-Györgyi University Medical School, Szeged, Hungary
Search for more papers by this authorJ. Kálmán
Departments of Psychiatry and Neurology, Szent-Györgyi University Medical School, Szeged, Hungary
Search for more papers by this authorA. Juhász
Departments of Psychiatry and Neurology, Szent-Györgyi University Medical School, Szeged, Hungary
Search for more papers by this authorP. Dickens
Royal Scottish National Hospital, Old Denny Road, Larbert, Scotland
Search for more papers by this authorCorresponding Author
T. Járdánházy
Departments of Psychiatry and Neurology, Szent-Györgyi University Medical School, Szeged, Hungary
János Kálmán, Departments of Psychiatry and Neurology, Szent-Györgyi University Medical School, Semmelweis u.B. H-6725 Szeged, HungarySearch for more papers by this authorA. Rimanóczy
Departments of Psychiatry and Neurology, Szent-Györgyi University Medical School, Szeged, Hungary
Search for more papers by this authorI. Boncz
Departments of Psychiatry and Neurology, Szent-Györgyi University Medical School, Szeged, Hungary
Search for more papers by this authorW. L. I. Parry-Jones
Department of Child and Adolescent Psychiatry, University of Glasgow, Royal Hospital for Sick Children, Yorkhill, Glasgow, Scotland
Search for more papers by this authorZ. Janka
Departments of Psychiatry and Neurology, Szent-Györgyi University Medical School, Szeged, Hungary
Search for more papers by this authorAbstract
Introduction - Inflammatory processes are suspected in the pathomechanism of Alzheimer's dementia (AD) but the serum and cerebrospinal fluid (CSF) levels of inflammatory cytokines are not yet determined in the different forms of the disorder. Subjects and methods - Interleukin-6 (IL-6) levels were examined in the sera and CSF of patients with mild-moderate and severe stage of late onset sporadic type of AD and in the sera of demented Down syndrome (DS) probands with similar stages of AD and compared with data of age-matched healthy controls.Results - Normal serum IL-6 levels were found in the mild-moderate stage, but significantly increased levels were found in the severe stage of both dementia groups. The CSF concentrations remained within the normal range in all groups. Positive correlations between the serum IL-6 levels and age and the severity of the disease were present. Conclusion - These findings suggest a disease stage dependent general activation of the immune system both in sporadic AD and in DS with AD.
References
- 1 Sherrington R, Rogaev EI, Liang Y et al. Cloning of a novel gene bearing missense mutations in early onset familial Alzheimer disease. Nature 1995: 375: 754–60.
- 2 Levy-Lahad E, Wasco W, Pookaj P et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995: 269: 973–7.
- 3 Rogaev EI, Sherrington R, Rogaeva EA et al. Familial Alzheimer's disease in kindreds with missense mutation in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1975: 376: 775–8.
- 4 Levy E, Carman MD, Fernandez-Madrid IJ et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990: 248: 1124–6.
- 5 Goathe A, Chartier-Harlin M, Mullan M et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991: 349: 704–6.
- 6 Tanzi RE, Gusella JE, Watkins P et al. Amyloid beta-protein gene cDNA, mRNA distribution and genetic linkage near the Alzheimer locus. Science 1987: 235: 880–4.
- 7 Wisniewski HM, Rabe A. Discrepancy between Alzheimer-type neuropathology and dementia in persons with Down's syndrome. Ann NY Acad Sci 1985: 477: 247–60.
- 8 Cork LC. Neuropathology of Down syndrome and Alzheimer disease. Am J Med Genet Suppl 1990: 7: 282–6.
- 9 Berkenbosch F, Biewenga J, Brouns M, Rozemuller JM, Strijbos P, van Dam AM. Cytokines and inflammatory proteins in Alzheimer's disease. Res Immunol 1993: 143: 657–63.
- 10 Licastro F, Parnetti L, Morini MC et al. Acute phase reactant alfa-1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease. Alzheimer Dis Assoc Disord 1995: 2: 112–18.
- 11 McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 1989: 107: 341–6.
- 12 Akiyama H, Kawamata T, Dedhar S, McGeer PL. Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue. J Neuro-immunol 1991: 32: 19–28.
- 13 May PC, Lampert-Etchells M, Johnson SA, Poirier J, Masters JN, Finch CE. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 1990: 5: 831–9.
- 14 Satoh T, Nakamura S, Taga T et al. Induction of neuronal differentation in PC12 cells by B-cell stimulatory factor 2/ interleukin 6. Mol Cell Biol 1988: 8: 3546–9.
- 15 Campbell IL, Abraham CR, Masliah E et al. Neurologic disease induced in transgenic mice by cerebral over-expression of interleukin-6. Proc Natl Acad Sci USA 1993: 90: 10061–5.
- 16 Del Bo RD, Angeretti N, Lucca E, De-Simoni MG, Forloni G. Reciprocal control of inflammatory cytokines, IL-1, and IL-6, and beta-amyloid production in cultures. Neurosci Lett 1995: 188: 70–4.
- 17 Brugg B, Dubreuil LY, Huber G, Wollman EE, Delhaye BM, Mariani J. Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. Proc Natl Acad Sci USA, 1995: 92: 3032–5.
- 18 De Vries HE, Blom-Roosemalen MCM, van Oosten M et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol 1996: 64: 37–43.
- 19 Nihira K, Foster R, Shellhaas M, Leland H. AAMD Adaptive Behavior Scale, 1974 revision. Washington DC : American Association on Mental Deficiency.
- 20 Schapiro MB, Haxby JB, Grady CL et al. Decline in cerebral glucose utilisation and cognitive function with aging in Down's syndrome. J Neurol Neurosurg Psychiatry 1987: 50: 766–74.
- 21 McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group. Neurology 1984: 34: 939–44.
- 22 American Psychiatric Association (APA): Diagnostic and Statistical Manual of Mental Disorders, ed 3, revised, Washington DC : American Psychiatric Association, 1987.
- 23 Folstein MF, Folstein ME, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975: 12: 189–98.
- 24 Van Duijn CM, Hofman A, Nagelkerken L. Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. Neurosci Lett 1990: 108: 350–4.
- 25 Bauer J, Strauss S, Schreitler-Gasser U et al. Interleukin-6 and alfa-2 macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett 1991: 285: 111–14.
- 26 Yamada K, Kono K, Umegaki H et al. Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer's-type of dementia. Neurosci Lett 1995: 186: 219–21.
- 27 Huberman M, Shalit F, Roth-Deri I et al. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J Neuroimmunol 1994: 52: 147–52.
- 28 Huberman M, Sredni B, Stern L, Kott E, Shalif F. IL-2 and IL-6 secretion in dementia: correlation with type and severity of disease. J Neurol Sci 1995: 130: 161–4.
- 29 Vandenabeele P, Fiers W. IS amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated “acute phase response” in the brain Immunol Today 1991; 217: 217–19.
- 30 Abraham CR. The role of acute-phase proteins alfa-l-antichymotrypsin in brain dysfunction and injury. Res Immunol 1992: 143: 631–6.
- 31
Erschler WB.
Interleukin-6: a cytokine for gerontologist.
J Am Geratr Soc
1993: 41: 176–81.
10.1111/j.1532-5415.1993.tb02054.x Google Scholar
- 32 Pirtilla T, Mehta PD, Frey H, Wisniewski HM. Alfa-1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. Neurobiol Aging 1994: 15: 313–17.
- 33 Lawlor BA, Swanwick GRJ, Feighery C, Walsh JB, Coakley D. Acute phase reactants in Alzheimer's disease. Biol Psychiatry 1996: 39: 1051–2.
- 34 McRae A, Dahlstrom A. Immune responses in brains of Alzheimer's and Parkinson's disease patients: hypothesis and reality. Rev Neurosci 1992: 3: 79–97.
- 35 Perlmutter LS, Barrow E, Chui HC. Microangiopathy, the vascular basement membrane and Alzheimer's disease: a review. Brain Res Bull 1990: 24: 677–86.
